Clinical Trial Search

Primary: Percentage Patients With Successful Outcome Investigator's Global Assessment (IGA) Score at Week 12, Intent to Treat (ITT) Population — 14.1; 15.4; 29.5; 16.4 Percentage…

Primary: Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts on the Face — -60.84; -62.17 percentage change in lesion counts — p=0.5947

Primary: Global Acne Grading System Score — 32; 30.33; 21.67; 27.5 score on a scale

Primary: Percentage of Participants With at Least a One Point Decrease in the Global Acne Assessment Score (GAAS) at Week 12 — 69.7; 81.4 Percentage of participants

Primary: Percent Change From Baseline in Total Lesion Counts at Week 12. — -64; -41 % of change

Primary: Inflammatory Lesion Counts — -29.9; -26.7; -24.8; -26.8 lesions

Primary: Number of Inflammatory Lesions (Papules and Pustules) — 6; 3; 10; 0 Lesions

Primary: Absolute Change in Inflammatory Lesion Counts — -7.7; -4.1; -11.2; -11.3 inflammatory acne lesions

Primary: Change in Number of Inflammatory Lesions — -30.1 Inflammatory lesions

Primary: Safety (Number of Participants With Treatment Related Adverse Events) — 4; 1; 2; 2 Participants

Primary: The Primary Endpoint of This Study is the Percent of Patients Who Achieved Clear (0) or Almost Clear (1) on IGA Scale at Week 16 — 78 percentage of participants — p=<0.008

Primary: Mean Change From Baseline in Total Lesion Count — -26.9 Lesions counted

Primary: Proportion of Success, Defined as Improvement of at Least 2 Grades From Baseline According to the IGA Scale Based on Facial Assessment — 16; 14.58; 11.54 Percentage of…

Primary: The Absolute Change From Baseline in the Inflammatory Lesion Count at the Final Visit — 12.8; 14.4; 17.6; 17.1 Number of Inflammatory Lesions — p=0.4344

Primary: Change From Baseline in Inflammatory Lesion Counts (Papules,Pustules, and Nodules) at Week 12 — 38.94; 40.78; -25.77; -24.82 Number of Lesions

Primary: Active Treatment Period: Total Acne-Specific Quality of Life Score at Week 20 — 100.7 score

Primary: The Primary Outcome is Overall Success, a Composite Endpoint Including Efficacy and Safety Measurements — 85; 73 count of participants

Primary: Number of Correct Responses to Questionnaire Items Immediately Before and After and Educational Lecture — 79; 79; 74; 79 participants

Primary: The Change in Number of Facial Inflammatory Acne-related Lesions. — 46; 23.7 Lesions

Primary: Absolute Change in the Inflammatory Lesion Counts on the Face — 30.1; 29.8; 15.4; 16.9 Lesions

Primary: Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment — 0; 0 participants

Primary: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear and a Score ≥2 Grades Less Than Baseline — 25.4; 14.7 percentage of participants

Primary: The Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12. — 16.39; 12.74 Lesion Count

Primary: Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12 — -21.9; -13.9 lesion count — p=<0.001

Primary: Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12 — -17.8; -10.6 lesion count — p=<0.001

Primary: Subject Reported Change From Baseline Scale — 0; 0; 7; 6 Participants

Primary: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear and a Score ≥2 Grades Less Than Baseline — 38.5; 11.5 percentage of participants

Primary: Absolute Change in Lesion Counts (Total, Inflammatory, and Non-inflammatory) From Baseline to Week 12 — -16.8; -18.1; -18.9; -18.8 Lesion count — p=0.692

Primary: Successful Outcome According to Investigator's Global Assessment (IGA) — 18; 19 participants — p=0.765

Primary: Safety as Measured by Reported Adverse Events — 2; 4; 5; 5 TEAEs